Knight Therapeutics Inc.
Knight Therapeutics Inc. (GUD.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
GUD.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsKnight Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.51B, an increase of 21.22% year-over-year from $0.45B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.45B | +$0.08B | +21.22% |
| 2024-12-31 | $0.37B | +$0.04B | +13.13% |
| 2023-12-31 | $0.33B | +$0.03B | +11.80% |
| 2022-12-31 | $0.29B | +$0.05B | +20.57% |
| 2021-12-31 | $0.24B | +$0.04B | +22.03% |
| 2020-12-31 | $0.20B | +$0.15B | +320.39% |
| 2019-12-31 | $0.05B | +$0.03B | +279.69% |
| 2018-12-31 | $0.01B | +$0.00B | +44.78% |
| 2017-12-31 | $0.01B | +$0.00B | +45.35% |
| 2016-12-31 | $0.01B | +$0.00B | +472.81% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Knight Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Knight Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Knight Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GUD.TO revenue · 4 questionsGUD.TO's trailing twelve-month (TTM) revenue is $0.51B. That is an increase of 21.22% year-over-year from $0.45B in FY2025.
▸ Source: FMP · Knight Therapeutics Inc. SEC filings · GAAP · Knight Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026